June 30, 2022 02:01 PM EDTUpdated July 1, 08:58 AM

PI3K inhibitor hit with an increased death risk warning from FDA after final trial results emerge

Zachary Brennan

Senior Editor

The FDA sent a fresh warning on Thursday about Secura Bio’s embattled PI3K inhibitor Copiktra (duvelisib), which may increase the risk of death and severe …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

PI3K inhibitor hit with an increased death risk warning from FDA after final trial results emerge

Zachary Brennan

Senior Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Exclusive: Florida cancer biotech raises $100M Series A

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

PI3K in­hibitor hit with an in­creased death risk warn­ing from FDA af­ter fi­nal tri­al re­sults emerge

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

PI3K inhibitor hit with an increased death risk warning from FDA after final trial results emerge

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Exclusive: Florida cancer biotech raises $100M Series A

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings